Results 121 to 130 of about 6,174 (184)

Binimetinib Regimen [PDF]

, 2020
openaire   +1 more source

Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAF^V600E-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison. [PDF]

ESMO Open
Planchard D, Mazières J, Grouin JM, Le Reun C, Luttenauer H, Boussahoua M, Macabeo B.   +6 more
europepmc   +1 more source

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial. [PDF]

Nat Commun
Rose AAN, Maxwell J, Rousselle E, Mukonoweshuro CL, Elkholi IE, Riaud M, Biondini M, Cianfarano E, Soria-Bretones I, Tobin C, McGuire M, Law RWY, Elia AJ, Wang BX, King I, Zhang T, Pugh TJ, Kamil ZS, Butler M, Shepherd FA, Leighl NB, Razak AA, Hansen A, Saibil SD, Bedard PL, Siegel PM, Siu LL, Cescon DW, Spreafico A.   +28 more
europepmc   +1 more source

Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials. [PDF]

BMJ Open
Peinemann F, Baradaran S, Arnolds KB, Hoemberg M.   +3 more
europepmc   +1 more source

Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer. [PDF]

J Clin Oncol
Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao MV, Sanborn RE, Morgensztern D, Usari T, Wilner K, Alejandro L, Rifi N, Zhang X, Riely GJ.   +20 more
europepmc   +1 more source

COLUMBUS part 1-7-year results for encorafenib and binimetinib in BRAF V600-mutant melanoma. [PDF]

Future Oncol
Schadendorf D.
europepmc   +1 more source

Pharmacokinetics of Binimetinib in Participants with Hepatic Impairment. [PDF]

Clin Pharmacokinet
Piscitelli J, Hahn E, Wollenberg L, Chavira R, Del Frari L, Reddy MB.   +5 more
europepmc   +1 more source

Targeted therapies and PARPi therapy response following ICI therapy failure in advanced melanoma: a case series. [PDF]

Melanoma Manag
Nassief G, Morecroft R, Phillipps J, Chen D, Ansstas G.   +4 more
europepmc   +1 more source

A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer. [PDF]

Cancer Res Commun
Manso L, Sánchez-Bayona R, Guerra JA, Cortés-Salgado A, Cejalvo JM, García-Saenz JA, Morales S, González-Cortijo L, Mourón S, Bueno MJ, Garma LD, Quintela-Fandino M.   +11 more
europepmc   +1 more source

POLARIS: encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis. [PDF]

Future Oncol
Menzies AM, Davies MA.
europepmc   +1 more source